Therefore, these results suggest that targeting PSMD14 upstream of the 20S proteasome may be a beneficial strategy for overcoming the PI resistance of cancers and the limitations of the current 20S CP-targeting PIs in cancer therapy. Here, PSMD14 is linked to cancer.